Navigation Links
BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease
Date:9/17/2008

LYNBROOK, N.Y. Sept. 17 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, announced today the initiation of a U.S. Phase IIb clinical trial in Peyronie's disease for its injectable collagenase, XIAFLEX (TM), by its partner Auxlium Pharmaceuticals, Inc.

"We are very pleased that our partner has chosen to advance this trial into a Phase IIb based on our extremely encouraging IIa results that showed a statistically significant reduction of angle of penile curvature and improvement in sexual satisfaction," stated Thomas Wegman, President of BioSpecifics Technologies Corp. "Peyronie's disease affects over 1 million men worldwide and there are no currently effective pharmaceutical therapies. We are happy to be one step closer to making this minimally invasive therapy available for those that need it and we look forward to the anticipated trial results that will be announced by the end of 2009."

The Phase IIb study is a randomized, double-blind, placebo-controlled study that is designed to assess the safety and efficacy of XIAFLEX, when administered two times a week every six weeks for up to three treatment cycles (2 x 3), in subjects with Peyronie's disease. The study will involve at least 120 patients at approximately 11 sites throughout the U.S., and patients will be monitored for 36 weeks following the first injection.

The trial is also designed to validate a proprietary Peyronie's Patient Reported Outcome (PRO) questionnaire, which will measure several domains of patients' sexual quality of life, over a 36 week period. The four domains measured by the PRO are penile pain, Peyronie's disease bother, intercourse discomfort and intercourse constraint.

To qualify for the study, patients must be able to maintain a rigid erection and have a penile contracture between 30 and 90 degrees. Patients will be stratified by the degree of penile curvature (i.e. 30 degrees to 60 degrees versus > 60 degrees) and then randomized into 4 treatment groups to receive either XIAFLEX or placebo with or without modeling of the penile plaque. Modeling refers to massaging of the plaque after the second injection of a treatment series and is intended to maximize the enzymatic effect of the XIAFLEX injection in the plaque. Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.

About Peyronie's Disease

Peyronie's disease is characterized by the presence of a collagen plaque on the shaft of the penis, which can distort an erection and make intercourse difficult or impossible in advanced cases. The plaque is not elastic and it does not stretch during erection. In some mild cases, the plaque can resolve spontaneously without medical intervention. The most common plaque forms on the top of the penis causing the penis to arc upward. In severe cases, the penis can be bent at a 90-degree angle during erection. Significant psychological distress has been noted in patients with Peyronie's disease who are sexually active. Frequent patient complaints include increased pain, painful erections, palpable plaque, penile deformity, and erectile dysfunction. Patients with Peyronie's disease have been reported to have an increased likelihood of having Dupuytren's disease, frozen shoulder, plantar fibromatosis, knuckle pads, hypertension and diabetes. Peyronie's disease typically affects males in the range of 40-70 years. The cause of Peyronie's disease is unknown, although some investigators have proposed that it may be due to trauma or an autoimmune component. A number of researchers have suggested that the incidence of Peyronie's disease has increased due to the use of erectile dysfunction drugs.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in June 2008. More information about the company may be found on its website at http://www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
2. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
3. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
4. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
5. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
6. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
7. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
8. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
9. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
10. Wound Management Technologies, Inc. Announces Evidence Based Study
11. Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017 This morning,s research ... stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals ... and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN ... space which is governed by the same governing ... the industry are wholesalers, retailers, pharmacies, and benefit ...
(Date:3/28/2017)... , March 28, 2017 RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Japan Patent Office (JPO) for the ... growth factor (CTGF) for the treatment or prevention ... skin fibrosis and proliferative retinopathy (Japanese Patent #: ...
(Date:3/27/2017)... March 27, 2017 The National University ... and data analytics company, signed a Memorandum of ... healthcare delivery in the region. ... Health Research and Technology (BIGHEART) at NUS and ... topics related to healthcare IT and medical device ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 29, 2017 , ... Dr. Isabella Wentz, ... launching a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey ... which emphasizes the fact that medication IS NOT the only solution to deal with ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... medical society dedicated to advancing the science and clinical practice of radiosurgery, ... RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce that ... Mr. Still was selected through a careful months-long search by the RBMA Board of ... our members, has been a part of building the RBMA since 1992,” said RBMA ...
(Date:3/28/2017)... ... 28, 2017 , ... Qualidigm , the mission-driven national ... a new, more expansive office space in order to accommodate its growing number ... office building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately ...
Breaking Medicine News(10 mins):